These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9440093)

  • 41. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis.
    Németh I; Túri S; Haszon I; Bereczki C
    Pediatr Nephrol; 2000 Jan; 14(1):13-7. PubMed ID: 10654322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of recombinant human erythropoietin on sodium balance in nondialysed children with chronic renal failure.
    Kavukçu S; Saatci U; Ciliv G; Söylemezoğlu O; Bakkaloğlu A; Besbas N; Ozen S
    Int Urol Nephrol; 1993; 25(6):611-5. PubMed ID: 8175282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin.
    Löw I; Grützmacher P; Bergmann M; Schoeppe W
    Clin Nephrol; 1989 Jan; 31(1):26-30. PubMed ID: 2521587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of erythropoietin on gonadotropin responses to gonadotropin-releasing hormone in uremic patients.
    Díez JJ; Iglesias P; Bajo MA; de Alvaro F; Selgas R
    Nephron; 1997; 77(2):169-75. PubMed ID: 9346383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of renal anaemia with recombinant human erythropoietin results in decreased red cell uptake of 45Ca.
    Linde T; Ronquist G; Sandhagen B; Wikström B; Frithz G; Pettersson L; Danielson BG
    Nephron; 1994; 68(4):419-26. PubMed ID: 7870225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin.
    Frei U; Nonnast-Daniel B; Schäffer J; Koch KM
    Contrib Nephrol; 1990; 82():72-8. PubMed ID: 2093530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients.
    Riedel E; Hampl H; Scigalla P; Nündel M; Kessel M
    Kidney Int Suppl; 1989 Nov; 27():S216-21. PubMed ID: 2636662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autonomic blockade and the Valsalva maneuver in patients on maintenance hemodialysis: a hemodynamic study.
    McGrath BP; Tiller DJ; Bune A; Chalmers JP; Korner PI; Uther JB
    Kidney Int; 1977 Oct; 12(4):294-302. PubMed ID: 599840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erythropoiesis and erythrocyte age distribution in hemodialysis patients undergoing erythropoietin therapy.
    Hampl H; Riedel E; Scigalla P; Stabell U; Wendel G
    Blood Purif; 1990; 8(3):117-25. PubMed ID: 2244989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal, hemodynamic, and hormonal responses to atrial natriuretic peptide infusions in normal man, and effect of sodium intake.
    Cuneo RC; Espiner EA; Nicholls MG; Yandle TG; Joyce SL; Gilchrist NL
    J Clin Endocrinol Metab; 1986 Oct; 63(4):946-53. PubMed ID: 2943757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin.
    Abdulhadi MH; Fouad-Tarazi FM; Thomas T; Bravo EL; Paganini EP
    Nephrol Dial Transplant; 1990; 5 Suppl 1():102-8. PubMed ID: 2129437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea.
    Møller DS; Lind P; Strunge B; Pedersen EB
    Am J Hypertens; 2003 Apr; 16(4):274-80. PubMed ID: 12670743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nocturnal blood pressure and relation to vasoactive hormones and renal function in hypertension and chronic renal failure.
    Jensen LW; Pedersen EB
    Blood Press; 1997 Nov; 6(6):332-42. PubMed ID: 9495658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anemia in hemodialysis patients: variables affecting this outcome predictor.
    Madore F; Lowrie EG; Brugnara C; Lew NL; Lazarus JM; Bridges K; Owen WF
    J Am Soc Nephrol; 1997 Dec; 8(12):1921-9. PubMed ID: 9402095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid peroxidation and vitamin E in red blood cells and plasma in hemodialysis patients under rhEPO treatment.
    Nenov D; Paskalev D; Yankova T; Tchankova P
    Artif Organs; 1995 May; 19(5):436-9. PubMed ID: 7625923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.
    Kampf D; Eckardt KU; Fischer HC; Schmalisch C; Ehmer B; Schostak M
    Nephron; 1992; 61(4):393-8. PubMed ID: 1501734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats.
    Moreau C; Larivière R; Kingma I; Grose JH; Lebel M
    Clin Exp Hypertens; 2000; 22(7-8):663-74. PubMed ID: 11131043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to erythropoietin in anaemic haemodialysis patients.
    Nielsen OJ; Thaysen JH
    J Intern Med; 1989 Aug; 226(2):89-94. PubMed ID: 2671248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.